Choose a language and wait for the translated text.
Shots
The US FDA has approved a citrate-free, high-concentration formulation for Yusimry as an interchangeable biosimilar to Humira (adalimumab)
Yusimry, a TNF blocker, is available in low and high concentration formulations via autoinjector, with the low-concentration formulation also available as a PFS
Emerge Bioscience holds the approved BLA for Yusimry, while Meitheal serves as its US Regulatory Agent & holds exclusive US commercialization rights under its license agreement with Emerge
Ref: Businesswire | Image: Meitheal Pharmaceuticals | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Meitheal Pharmaceuticals Reports US FDA Approval of High-Concentration Formulation of Yusimry (Biosimilar, Humira) appeared first on PharmaShots.
